A phase IIa trial investigating the cardiometabolic effects of gevokizumab in patients with type 2 diabetes mellitus.
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2011
At a glance
- Drugs Gevokizumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors XOMA
- 04 Aug 2011 Six-month top-line results reported in a XOMA Media Release.
- 05 Oct 2009 New trial record.
- 01 Oct 2009 This trial is in its final stages of design. XOMA anticipates initiating this trial in the first quarter of 2010, according to a company media release.